Portal de Periódicos da CAPES

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

2016; Massachusetts Medical Society; Volume: 375; Issue: 8 Linguagem: Inglês

10.1056/nejmoa1602253

1533-4406

Fátima Cardoso, Laura J. vanʼt Veer, Jan Bogaerts, Leen Slaets, Giuseppe Viale, Suzette Delaloge, Jean‐Yves Pierga, Étienne Brain, Sylvain Causeret, Mauro Delorenzi, Annuska M. Glas, Vassilis Golfinopoulos, Theodora Goulioti, Susan Knox, Erika Matos, Bart Meulemans, Peter A. Neijenhuis, Ulrike Nitz, Rodolfo Passalacqua, Peter M. Ravdin, Isabel T. Rubio, Mahasti Saghatchian, Tineke J. Smilde, Christos Sotiriou, Lisette Stork, Carolyn Straehle, Geraldine Thomas, Alastair M. Thompson, Jacobus M. van der Hoeven, Peter Vuylsteke, René Bernards, Konstantinos Tryfonidis, Emiel J. Rutgers, Martine Piccart,

Lung Cancer Treatments and Mutations

The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical outcome in women with early-stage breast cancer. We sought to provide prospective evidence of the clinical utility of the addition of the 70-gene signature to standard clinical–pathological criteria in selecting patients for adjuvant chemotherapy.